Related Experiment Videos
Antiestrogen resistance in ER positive breast cancer cells
S Paik1, D P Hartmann, R B Dickson
1Vincent T. Lombardi Cancer Center, Georgetown University, Washington, DC 20007.
Abstract:
Acquisition of the antiestrogen resistance by breast cancer cells in vivo may result from a variety of mechanisms. The main pathway appears to involve loss of estrogen receptor (ER) expression or selection for ER negative cells among heterogenous population of tumor cells. However, clinical data suggest that, in about 30% of the cases, antiestrogen resistance arises even in the presence of estrogen receptors. Postulated mechanisms leading to the latter phenotype include selection for variant receptor forms during treatment, development of novel metabolic pathways for the drug, loss of nuclear co-factors, or activation of signal transduction pathway that cross activate ER signals. We have used an in vitro experimental system utilizing LY-2 cell line, an ER positive and antiestrogen resistant MCF-7 cell variant, to study the mechanism of antiestrogen resistance in the presence of functional ER. Result from a complementation experiment suggests that LY-2 phenotype is a recessive trait. Cloning of the genetic defect in the LY-2 cells would provide further insight for the mechanism of antiestrogen resistance in ER positive breast cancer cells.
Insights
Antiestrogen resistance in breast cancer can occur even with estrogen receptors (ER) present. Research suggests a recessive genetic defect in ER-positive cells may drive this resistance, offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Antiestrogen therapy is a cornerstone in treating estrogen receptor (ER)-positive breast cancer.
- Resistance to antiestrogens is a significant clinical challenge, occurring through various mechanisms.
- Approximately 30% of resistance cases develop despite the presence of functional ER.
Purpose of the Study:
- To investigate the mechanisms of antiestrogen resistance in ER-positive breast cancer cells.
- To identify genetic factors contributing to resistance in the presence of functional ER.
- To utilize an in vitro model (LY-2 cell line) to study this phenomenon.
Main Methods:
- Established an in vitro experimental system using the LY-2 cell line, an ER-positive, antiestrogen-resistant MCF-7 variant.
- Conducted complementation experiments to analyze the genetic basis of the resistant phenotype.
- Focused on studying resistance mechanisms in cells retaining functional ER.
Main Results:
- The LY-2 cell line exhibits antiestrogen resistance despite maintaining estrogen receptor expression.
- Complementation experiments indicated that the antiestrogen resistance phenotype in LY-2 cells is a recessive trait.
- This suggests a specific genetic defect underlies resistance in ER-positive cells.
Conclusions:
- Antiestrogen resistance in ER-positive breast cancer can be mediated by recessive genetic alterations.
- Identifying the specific genetic defect in LY-2 cells could reveal novel therapeutic targets.
- Further research into these genetic defects may improve treatment strategies for resistant breast cancer.